

SLR:slr:dm 12/4/02 154945.doc
PATENT

Attorney Reference Number 4239-62631
Application Number 09/634,369

Please add the following new claims:

33. (New) The method of claim 28, wherein contacting a cell comprises administration of EETs, epoxyeicosatrienoic acid metabolic products, epoxyeicosatrienoic acid, ^{analogs and} dihydroxyeicosatrienoic acid ^{or} analogs, ^{or} combinations thereof to a subject.

34. (New) The method of claim 33, wherein the wherein the administration comprises producing EETs from a cytochrome P450 epoxygenase.

35. (New) The method of claim 34, wherein the EET is [11,12]-EET, [14,15]-EET, or combinations thereof, and wherein the epoxyeicosatrienoic acid metabolic product is [11,12]-DHET.

36. (New) The method of claim 34, wherein the cytochrome P450 epoxygenase is selected from the group consisting of CYP1A, CYP2B, CYP2C, CYP2E, and CYP2J enzymes.

37. (New) The method of claim 36, wherein the CYP2J enzyme is a mammalian homologue of CYP2J2.

38. (New) The method of claim 37, wherein the mammalian homologue is human CYP2J2.

39. (New) The method of claim 37, wherein the mammalian homologue is rat CYP2J3 or mouse CYP2J5.

40. (New) The method of claim 28 wherein the EET is [11,12]-EET or [14,15]-EET, and wherein the epoxyeicosatrienoic acid metabolic products is [11,12]-DHET.

RESPONSE

By this amendment, claims 10-19, 21 and 25-27 would be cancelled, and claims 33-40 would be added. Therefore, claims 28 and 33-40 would be pending in this application.

Support for the new claims can be found in the specification and original claims as follows: